SRPT Sarepta Therapeutics Inc.

124.95
+2.98  (+2%)
Previous Close 121.97
Open 123.35
Price To Book 8.45
Market Cap 9,288,835,104
Shares 74,340,417
Volume 1,239,233
Short Ratio
Av. Daily Volume 1,353,266

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due 3Q 2019.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 dosing to be completed 2Q 2019.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Aims to have dosing and safety insight by 1H 2020.
SRP-5051 - PPMO
Duchenne muscular dystrophy
PDUFA date under priority review August 19, 2019 .
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 data February 27, 2019 noted mean of 51% beta-sarcoglycan positive fibers.
MYO-101
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 initiation of dosing announced February 14, 2019.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)
Phase 2 Study 2 readout due by end of 2020.
SRP-9001
Duchenne muscular dystrophy

Latest News

  1. Gene therapies to test FDA's approach to regulating drugs after launch, experts say
  2. Edited Transcript of SRPT earnings conference call or presentation 7-Aug-19 8:30pm GMT
  3. Xontogeny, accelerator launched by former Sarepta CEO, preps five new biotechs
  4. Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares
  5. Why Sarepta Therapeutics Stock Tanked on Thursday
  6. Sarepta Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  7. Why Zillow Group, Sarepta Therapeutics, and CenturyLink Slumped Today
  8. Sarepta stock tumbles after Duchenne gene therapy complication
  9. This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
  10. Sarepta stock drops on erroneous adverse event report to FDA
  11. Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)
  12. UPDATE 1-Patient in Sarepta gene therapy trial develops serious illness; shares plunge
  13. Sarepta says adverse event report for DMD gene therapy erroneously submitted
  14. Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
  15. Sarepta Therapeutics (SRPT) Q2 2019 Earnings Call Transcript
  16. What You'll Want to Know About Sarepta Therapeutics' Q2 Results
  17. Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy
  18. Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
  19. Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
  20. A Preview Of Sarepta Therapeutics Q2 Earnings